HC Wainwright Has Negative Outlook of RARE FY2025 Earnings

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Stock analysts at HC Wainwright dropped their FY2025 earnings estimates for Ultragenyx Pharmaceutical in a note issued to investors on Monday, January 5th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will post earnings of ($5.26) per share for the year, down from their prior forecast of ($4.85). HC Wainwright has a “Buy” rating and a $60.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($5.18) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($1.30) EPS, Q4 2026 earnings at ($1.00) EPS and FY2026 earnings at ($5.32) EPS.

RARE has been the subject of several other research reports. TD Cowen cut their price target on Ultragenyx Pharmaceutical from $86.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Barclays cut their target price on shares of Ultragenyx Pharmaceutical from $81.00 to $50.00 and set an “overweight” rating for the company in a research report on Monday, November 24th. Leerink Partners lowered their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 30th. Robert W. Baird cut their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $47.00 and set an “outperform” rating for the company in a report on Tuesday, December 30th. Finally, Wells Fargo & Company reduced their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $45.00 and set an “overweight” rating for the company in a research note on Tuesday, December 30th. Sixteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $72.29.

Ultragenyx Pharmaceutical Price Performance

NASDAQ:RARE opened at $23.21 on Wednesday. The company has a market capitalization of $2.24 billion, a P/E ratio of -3.91 and a beta of 0.15. The business has a fifty day simple moving average of $31.88 and a two-hundred day simple moving average of $31.40. Ultragenyx Pharmaceutical has a 1 year low of $18.41 and a 1 year high of $46.50.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.58). Ultragenyx Pharmaceutical had a negative return on equity of 414.17% and a negative net margin of 91.95%.The company had revenue of $159.93 million for the quarter, compared to analysts’ expectations of $167.42 million. During the same quarter in the previous year, the business earned ($1.40) EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis.

Institutional Investors Weigh In On Ultragenyx Pharmaceutical

Large investors have recently added to or reduced their stakes in the business. Parallel Advisors LLC grew its position in Ultragenyx Pharmaceutical by 1,061.9% during the second quarter. Parallel Advisors LLC now owns 732 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 669 shares in the last quarter. Assetmark Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares during the last quarter. Huntington National Bank grew its holdings in shares of Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 393 shares in the last quarter. Danske Bank A S bought a new position in shares of Ultragenyx Pharmaceutical in the third quarter worth approximately $39,000. Finally, Smartleaf Asset Management LLC raised its stake in Ultragenyx Pharmaceutical by 205.4% in the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares in the last quarter. Institutional investors own 97.67% of the company’s stock.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of the firm’s stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $36.38, for a total value of $112,086.78. Following the completion of the transaction, the chief financial officer directly owned 95,146 shares of the company’s stock, valued at $3,461,411.48. This trade represents a 3.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have sold 11,108 shares of company stock valued at $365,262. Corporate insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical News Summary

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Leerink Partners issued an “Outperform” / buy view, reinforcing buy-side support for RARE and signaling confidence in the story. Ultragenyx Pharmaceutical (RARE) Gets a Buy from Leerink Partners
• Positive Sentiment: Citi reiterated a buy on Ultragenyx, adding to the cluster of favorable analyst guidance that can support upside if clinical/commercial execution continues. Citi Remains a Buy on Ultragenyx Pharmaceutical (RARE)
• Positive Sentiment: HC Wainwright maintained a Buy and updated EPS forecasts (mixed quarter-by-quarter tweaks but raised FY2026 view) while keeping a $60 price target — a supportive institutional analyst view that can attract buyers despite near-term losses. MarketBeat: Ultragenyx analyst notes (HC Wainwright)
• Positive Sentiment: Management visibility: CEO Emil Kakkis will present at the J.P. Morgan Healthcare Conference (Jan 12). The presentation and webcast provide an opportunity to update investors on clinical/program milestones and commercial traction. Ultragenyx CEO to Present at J.P. Morgan Healthcare Conference
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Ultragenyx, a development that raises litigation risk and can create short-term selling pressure and uncertainty for shareholders. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims
• Negative Sentiment: Press coverage flagged a clinical setback and mounting challenges for Ultragenyx programs; clinical news can materially affect biotech valuations and likely contributed to downside. Ultragenyx Shares Face Mounting Challenges After Clinical Setback
• Negative Sentiment: Guggenheim lowered its price target to $52, trimming upside expectations and adding downward pressure amid competing analyst bulls. Guggenheim Lowers Ultragenyx Price Target to $52

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.